Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of NPC-1 defined as one of the following~   * Two NPC-1 mutations on genotyping~  * One NPC-1 mutation and positive filipin staining (current or prior)~  * Vertical supranuclear gaze palsy \[VSNGP\] plus either ≥ one NPC-1 mutation or positive filipin staining and no NPC-2 mutations~2. NIH NPC Severity Score \<30 and with no more than 4 individual domains with a score ≥ 3.~3. Age range: 2 years upwards~   * Inclusion of the first three paediatric patients will be restricted to individuals aged ≥ 5 years. Once the first three paediatric patients have safely completed stage 1, study entry will be open to all ages ≥2 years as per the protocol~4. Negative pregnancy test for females of child bearing potential~5. Written, informed consent~   -~Exclusion Criteria:~1. The presence of NPC-2 mutations on genotyping~2. Previous receipt of cyclodextrin therapy~3. Lanksy score \< 50 if aged ≤16 or Karnofsky score \< 40 if aged \> 16.~4. Inability to comply with the proposed protocol assessments~5. Concurrent treatment with any type of cholesterol lowering agents such as statins, fibrates, ezetimibe~6. Concurrent medical conditions representing a contraindication to any of the study medications~7. Stage 3 renal impairment or worse as indicated by eGFR\< 60mL/min using the MDRD equation~8. Clinical evidence of acute liver disease including symptoms of jaundice or right upper quadrant pain or INR \>1. 8~9. Involvement in another interventional clinical trial within the previous 6 months~10. Weight \>100 kg~11. Females of childbearing potential who are not willing to use a method of highly effective contraception (hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, or true abstinence) during the study and the follow-up period. True abstinence can only be in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception.~12. Females who are breastfeeding~    -

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg (Type: ACTIVE_COMPARATOR): Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
- Hydroxy-propyl-beta-cyclodextrin IV 2000 mg/kg (Type: ACTIVE_COMPARATOR): Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
- Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg (Type: ACTIVE_COMPARATOR): Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).